Rhenman & Partners Asset Management AB Has $16.50 Million Holdings in Edwards Lifesciences Corporation $EW

Rhenman & Partners Asset Management AB lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 24.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 193,500 shares of the medical research company’s stock after purchasing an additional 38,500 shares during the period. Edwards Lifesciences accounts for about 1.5% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 24th biggest holding. Rhenman & Partners Asset Management AB’s holdings in Edwards Lifesciences were worth $16,496,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Wealthspire Advisors LLC lifted its stake in shares of Edwards Lifesciences by 33.4% in the 4th quarter. Wealthspire Advisors LLC now owns 15,338 shares of the medical research company’s stock valued at $1,308,000 after purchasing an additional 3,842 shares during the last quarter. Tiemann Investment Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $217,000. Allianz SE lifted its stake in shares of Edwards Lifesciences by 295.9% in the 4th quarter. Allianz SE now owns 9,857 shares of the medical research company’s stock valued at $840,000 after purchasing an additional 7,367 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after purchasing an additional 136 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in shares of Edwards Lifesciences by 53.7% in the 4th quarter. Advisors Asset Management Inc. now owns 27,481 shares of the medical research company’s stock valued at $2,343,000 after purchasing an additional 9,598 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Evercore reaffirmed an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Finally, TD Cowen reissued a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $95.96.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 81,038 shares of company stock valued at $6,683,255 in the last ninety days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Down 0.9%

Edwards Lifesciences stock opened at $85.02 on Friday. The firm has a market cap of $48.95 billion, a price-to-earnings ratio of 45.22, a P/E/G ratio of 2.15 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $89.48. The firm has a fifty day moving average price of $82.77 and a two-hundred day moving average price of $83.11.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the business earned $0.64 earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.